engage checkpoint medical linkedin twitter

Update from ASCO 2022 – Sarcoma

Update from ASCO 2022 – Sarcoma

SARCOMA update by Prof. Jonathan Trent, University of Miami Hospital, USA

SARCOMA update by Prof. Jonathan Trent, University of Miami Hospital, USA

Prof. Jonathan Trent

Portrait of Jonathan Trent
Prof. Jonathan Trent

Medical Oncology

University of Miami Health System

United States (US)

preview next

time | open 2 min | Jun 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Hi. This is Dr. John Trent here at ASCO to discuss the results of the rEECur trial.

Patients with refractory and relapsed Ewing sarcoma only have less than 15% five-year survival rate.

Treatment is controversial. In this update of the rEECur trial patients were randomised to either topotecan plus Cytoxan (cyclophosphamide) vs high-dose ifosfamide 15 g/m2 (3g/m2 D1-5).

As it turns out, patients who were randomised to topotecan plus Cytoxan (cyclophosphamide) had a 10.5 month median overall survival and a 45% one year survival rate.

On the other hand, those patients randomised to high-dose ifosfamide 15 g/m2 (3g/m2 D1-5) enjoyed a 15.4 month overall survival and a 55% one year survival rate.

All of these benefits from high-dose ifosfamide were statistically significant.

This data is applicable to the standard of care of therapy and is indeed practice changing today. Thank you.

Prof. Trent discusses the Sarcoma presentation presented at the ASCO 2022 late breaker pleanary session 

  • Phase 3 assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. McCabe M, et al. Abstract LBA2, ASCO 2022

For news on other ASCO 2022 late-breakers covering rectal cancer, breast cancer and multiple myeloma, visit our summary video here

SARCOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest